DK3534936T3 - Tolerogen dna-vaccine - Google Patents

Tolerogen dna-vaccine Download PDF

Info

Publication number
DK3534936T3
DK3534936T3 DK17801363.7T DK17801363T DK3534936T3 DK 3534936 T3 DK3534936 T3 DK 3534936T3 DK 17801363 T DK17801363 T DK 17801363T DK 3534936 T3 DK3534936 T3 DK 3534936T3
Authority
DK
Denmark
Prior art keywords
tolerogen
dna vaccine
vaccine
dna
tolerogen dna
Prior art date
Application number
DK17801363.7T
Other languages
English (en)
Inventor
Jay Chaplin
Michael Wijaranakula
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority claimed from PCT/EP2017/077949 external-priority patent/WO2018083111A1/en
Application granted granted Critical
Publication of DK3534936T3 publication Critical patent/DK3534936T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
DK17801363.7T 2016-11-01 2017-11-01 Tolerogen dna-vaccine DK3534936T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662415717P 2016-11-01 2016-11-01
EP17150037 2017-01-02
EP17169019 2017-05-02
EP17177289 2017-06-22
EP17198041 2017-10-24
PCT/EP2017/077949 WO2018083111A1 (en) 2016-11-01 2017-11-01 Tolerogenic dna vaccine

Publications (1)

Publication Number Publication Date
DK3534936T3 true DK3534936T3 (da) 2020-11-02

Family

ID=60190888

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17801363.7T DK3534936T3 (da) 2016-11-01 2017-11-01 Tolerogen dna-vaccine

Country Status (24)

Country Link
US (1) US11466278B2 (da)
EP (3) EP3534936B1 (da)
JP (3) JP7084388B2 (da)
KR (1) KR102476552B1 (da)
CN (2) CN109922827B (da)
AU (1) AU2017353323B2 (da)
BR (1) BR112019007408A2 (da)
CA (1) CA3042321A1 (da)
CL (1) CL2019001181A1 (da)
CO (1) CO2019004193A2 (da)
DK (1) DK3534936T3 (da)
ES (2) ES2834329T3 (da)
HR (1) HRP20201710T1 (da)
HU (1) HUE051766T2 (da)
IL (1) IL266237B (da)
MX (1) MX2019004774A (da)
MY (1) MY190102A (da)
PE (1) PE20190841A1 (da)
PH (1) PH12019500851A1 (da)
PL (1) PL3534936T3 (da)
RS (1) RS61138B1 (da)
RU (1) RU2752608C2 (da)
SA (1) SA519401615B1 (da)
SI (1) SI3534936T1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
PL3534936T3 (pl) * 2016-11-01 2021-01-25 Novo Nordisk A/S Szczepionka tolerogennego dna
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine
CN113461796A (zh) * 2021-08-04 2021-10-01 深圳晶蛋生物医药科技有限公司 一种重组sglt2蛋白及其应用
EP4340855A1 (en) * 2021-08-13 2024-03-27 Triovance Holding LLC A skin substitute composition and methods of producing and using the same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518395D0 (en) * 1995-09-08 1995-11-08 Therexsys Ltd Plasmid stabilization
AU5689898A (en) 1996-12-05 1998-06-29 University Of Florida Il-10 and tgf-beta for treating autoimmune disease
US7030098B2 (en) 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
US6884785B2 (en) 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
US7531352B2 (en) 2000-04-20 2009-05-12 The United States Of America As Represented By The Department Of Health And Human Services Inducible plasmid vector encoding TGF-β and use thereof
AU2001292610A1 (en) 2000-09-08 2002-03-22 University Of Maryland Biotechnology Institute Genetically engineered co-expression dna vaccines, construction methods and uses thereof
USD459798S1 (en) 2001-03-26 2002-07-02 Aventis Pharma S.A. Pill tablet
SE0102204D0 (sv) 2001-06-21 2001-06-21 Leif Isaksson New method
NZ533294A (en) * 2001-11-21 2007-06-29 Univ Leland Stanford Junior Polynucleotide therapy for diabetes associated with self-proteins, -polypeptides and -peptides
US20040110295A1 (en) 2002-05-28 2004-06-10 Maxygen, Inc., A Delaware Corporation Nucleic acid vectors
RU2228198C1 (ru) * 2002-08-21 2004-05-10 Полетаев Александр Борисович Способ коррекции патологического аутоиммунного процесса при сахарном диабете
DE60333786D1 (de) 2002-11-21 2010-09-23 Univ R Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen
US20050026189A1 (en) 2003-05-29 2005-02-03 Liangsu Wang Microbial operons
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
WO2005089101A2 (en) 2004-02-03 2005-09-29 Dana-Farber Cancer Institute, Inc. Non-pathogenic listeria vaccine vectors and methods of treatment therewith
CN101277722A (zh) * 2005-08-06 2008-10-01 王庆华 用于预防和治疗ⅰ型糖尿病的组合物及方法
CA2624615A1 (en) 2005-10-05 2007-04-19 Bayhill Therapeutics, Inc. Compositions and methods for treatment of autoimmune disease
CA2550133A1 (en) 2006-02-16 2007-08-16 The Governors Of The University Of Alberta Temperature regulated gene expression
US20100048679A1 (en) 2006-06-13 2010-02-25 Bayhill Therapeutics, Inc. Polynucleotide therapy
WO2009111031A2 (en) 2008-03-04 2009-09-11 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
MX2011012234A (es) 2009-05-22 2012-03-07 Merial Ltd Plasmido libre de antibiotico.
EP2461828B1 (en) 2009-07-31 2017-06-21 President and Fellows of Harvard College Programming of cells for tolerogenic therapies
WO2011091138A1 (en) 2010-01-20 2011-07-28 Bayhill Therapeutics, Inc. Combination therapy to treat autoimmune diseases
WO2012041867A2 (en) 2010-09-27 2012-04-05 China Agricultural University Combined antigen and dna vaccine for preventing and treating autoimmune diseases
WO2012062697A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Combination therapy for type 1 diabetes
WO2013036914A1 (en) 2011-09-08 2013-03-14 University Of Florida Research Foundation, Inc. Materials and methods for modulating immune responses
WO2014035457A1 (en) 2012-08-29 2014-03-06 Nature Technology Corporation Dna plasmids with improved expression
US9636386B2 (en) * 2013-03-15 2017-05-02 City Of Hope Attenuated Salmonella bacteria and methods of using
WO2016057986A1 (en) * 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
WO2016162385A1 (en) 2015-04-07 2016-10-13 Consejo Superior De Investigaciones Científicas (Csic) Bacterial system for the identification of amyloidogenic peptides and the screening of inhibitors of amyloidosis
US11046732B2 (en) 2015-12-11 2021-06-29 Wacker Chemie Ag Microorganism strain and method for antibiotic-free, fermentative preparation of low molecular weight substances and proteins
TWI728201B (zh) 2016-11-01 2021-05-21 丹麥商諾佛 儂迪克股份有限公司 耐受性ｄｎａ疫苗
PL3534936T3 (pl) * 2016-11-01 2021-01-25 Novo Nordisk A/S Szczepionka tolerogennego dna
USD813372S1 (en) 2017-02-22 2018-03-20 Celgene Corporation Pharmaceutical tablet
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine

Also Published As

Publication number Publication date
IL266237B (en) 2022-08-01
PH12019500851A1 (en) 2019-12-02
CN109922827B (zh) 2024-03-01
JP6721790B2 (ja) 2020-07-15
CA3042321A1 (en) 2018-05-11
EP3534936B1 (en) 2020-10-21
PL3534936T3 (pl) 2021-01-25
CN109890967A (zh) 2019-06-14
SA519401615B1 (ar) 2023-01-31
ES2829574T3 (es) 2021-06-01
CN109922827A (zh) 2019-06-21
HRP20201710T1 (hr) 2020-12-25
JP2019532660A (ja) 2019-11-14
US11466278B2 (en) 2022-10-11
KR20190076020A (ko) 2019-07-01
HUE051766T2 (hu) 2021-03-29
IL266237A (en) 2019-06-30
EP3535399B1 (en) 2020-10-07
JP2019532659A (ja) 2019-11-14
CL2019001181A1 (es) 2019-07-05
CO2019004193A2 (es) 2019-07-31
SI3534936T1 (sl) 2020-12-31
AU2017353323B2 (en) 2024-02-29
BR112019007408A2 (pt) 2019-07-02
RU2019115540A (ru) 2020-12-03
US20190241898A1 (en) 2019-08-08
ES2834329T3 (es) 2021-06-17
RS61138B1 (sr) 2020-12-31
MX2019004774A (es) 2019-08-05
JP7084388B2 (ja) 2022-06-14
PE20190841A1 (es) 2019-06-17
KR102476552B1 (ko) 2022-12-13
JP2020062057A (ja) 2020-04-23
RU2019115540A3 (da) 2021-01-28
MY190102A (en) 2022-03-28
RU2752608C2 (ru) 2021-07-29
EP3799882A1 (en) 2021-04-07
EP3535399A1 (en) 2019-09-11
AU2017353323A1 (en) 2019-05-02
EP3534936A1 (en) 2019-09-11
CN109890967B (zh) 2024-03-19

Similar Documents

Publication Publication Date Title
DK3433368T3 (da) Transreplikerende rna
DK3393510T3 (da) Zikavirusvaccine
DK3400291T3 (da) Manipuleret virus
DK3405050T3 (da) Børnesikret snusbeholder
DK3234132T3 (da) Ligand-modificerede dobbeltstrengede nukleinsyrer
DK3167044T3 (da) Mikrofluidindretning
DK3436823T3 (da) Antigen-array
DK3335532T3 (da) Tandharve
DK3445708T3 (da) Stigbøjle
DK3534936T3 (da) Tolerogen dna-vaccine
DK3402792T3 (da) Quinolin-2-on-derivater
DK3102702T3 (da) Fejlfri sekvensering af DNA
DK3509963T3 (da) Pallecontainer
DK3246652T3 (da) Varmeindretning
DK3307436T3 (da) Mikrofluidanordning
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
FR3024324B3 (fr) Souffleur
DK3062824T3 (da) Telomerase-kodende dna-vaccine
DK3528948T3 (da) Mikrofluidsystem
DK3575238T3 (da) Pallecontainer
DK3274092T3 (da) Mikrofluidikanordning
CL2016001249S1 (es) Conjunto soplador
DK3471535T3 (da) Dyrelift
DK3323708T3 (da) Bovfender
DK3405212T3 (da) Cancervacciner